Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells

Citations Over TimeTop 1% of 2011 papers

Abstract

A novel cell-targeting, pH-sensitive polymeric carrier was employed in this study for delivery of the anticancer drug bortezomib (BTZ) to cancer cells. Our strategy is based on facile conjugation of BTZ to catechol-containing polymeric carriers that are designed to be taken up selectively by cancer cells through cell surface receptor-mediated mechanisms. The polymer used as a building block in this study was poly(ethylene glycol), which was chosen for its ability to reduce nonspecific interactions with proteins and cells. The catechol moiety was exploited for its ability to bind and release borate-containing therapeutics such as BTZ in a pH-dependent manner. In acidic environments, such as in cancer tissue or the subcellular endosome, BTZ dissociates from the polymer-bound catechol groups to liberate the free drug, which inhibits proteasome function. A cancer-cell-targeting ligand, biotin, was presented on the polymer carriers to facilitate targeted entry of drug-loaded polymer carriers into cancer cells. Our study demonstrated that the cancer-targeting drug-polymer conjugates dramatically enhanced cellular uptake, proteasome inhibition, and cytotoxicity toward breast carcinoma cells in comparison with nontargeting drug-polymer conjugates. The pH-sensitive catechol-boronate binding mechanism provides a chemoselective approach for controlling the release of BTZ in targeted cancer cells, establishing a concept that may be applied in the future toward other boronic acid-containing therapeutics to treat a broad range of diseases.

Related Papers

• → Analysis on the current status of targeted drug delivery to tumors(2012)405 cited
• → Colon Targeted Drug Delivery Systems -An Overview(2008)70 cited
• → Research and Application of Oral Colon Targeted Drug Delivery System(2014)3 cited
• Review on overview of colon targeting drug dilivery system(2021)
• → Review On Targeted Drug Delivery System And Its Carriers As Drug Targeted To A Specific Organ(2023)